Using inhaled ICG to improve lung surgery in children
Application of Atomized Inhalation ICG in Thoracoscopic Surgery for Pulmonary Sequestration in Children: a Multicentre Prospective Study
This study is testing if inhaling a special dye before lung surgery can help doctors see better and improve outcomes for children with lung problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 3 Months to 14 Years |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06302985 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of using aerosolized indocyanine green (ICG) solution before surgery to enhance the accuracy of thoracoscopic resection of congenital lung malformations in children. Patients will inhale the ICG solution 30 minutes prior to surgery, allowing for better visualization of lung lesions during the procedure. The study includes preoperative evaluations and utilizes fluorescence imaging during surgery to differentiate between healthy and affected lung tissue. The goal is to improve surgical outcomes for children with specific lung conditions.
Who should consider this trial
Good fit: Ideal candidates are children diagnosed with congenital lung malformations through CT or MRI scans.
Not a fit: Patients under 3 months or over 14 years of age, or those with life-threatening diseases or severe pulmonary infections, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise surgical interventions and improved recovery for children with congenital lung malformations.
How similar studies have performed: While the use of ICG in surgical settings has shown promise, this specific application for congenital lung malformations is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * children with congenital lung malformations diagnosed by CT or MRI scan Exclusion Criteria: * 1\. ages \<3 months and \>14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection
Where this trial is running
Wuhan, Hubei
- Tongji Hospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Tianqi Zhu, MD — Tongji Hospital
- Study coordinator: Tianqi Zhu, MD
- Email: zhutianqi84@163.com
- Phone: 0086-13986295423
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.